The clinical development of the bryostatins

Anti-Cancer Drugs

Volumn 13, Issue 7, 2002, Pages 673-683

  Clamp, A ^a   Jayson, G C ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

Bryostatin; Protein kinase C; Signal transduction

Indexed keywords

ANALGESIC AGENT; BRYOSTATIN; BRYOSTATIN 1; BRYOSTATIN 10; BRYOSTATIN 4; BRYOSTATIN 5; BRYOSTATIN 7; BRYOSTATIN 8; CISPLATIN; CLADRIBINE; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOTOXIC AGENT; DOXORUBICIN; FLUDARABINE; GABAPENTIN; GEMCITABINE; GLYCOPROTEIN P; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; INTERLEUKIN 3; IONOMYCIN; PACLITAXEL; PREDNISOLONE; PREDNISONE; PROTEIN KINASE C; RETINOIC ACID; UNCLASSIFIED DRUG; VINCRISTINE; ANTINEOPLASTIC AGENT; LACTONE; MACROLIDE;

ANTINEOPLASTIC ACTIVITY; BRYOZOA; BUGULA NERITINA; CALCIUM CELL LEVEL; CANCER; CELL DIFFERENTIATION; CLINICAL TRIAL; CONTINUOUS INFUSION; CYTOKINE PRODUCTION; DRUG CLEARANCE; DRUG DESIGN; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG POTENTIATION; DRUG STRUCTURE; ENZYME ACTIVITY; HEADACHE; HEMATOPOIESIS; HEMATURIA; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; IN VIVO STUDY; LETHARGY; LYMPHOCYTE ACTIVATION; MAXIMUM TOLERATED DOSE; MODULATION; MYALGIA; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHLEBITIS; PRIORITY JOURNAL; RADIATION PROTECTION; REVIEW; TREATMENT OUTCOME; XENOGRAFT; ADOPTIVE IMMUNOTHERAPY; ANIMAL; NEOPLASM;

ANIMAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; HUMAN; IMMUNOTHERAPY, ADOPTIVE; LACTONES; NEOPLASMS; ANIMALS; HUMANS; MACROLIDES;

EID: 0036667939     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200208000-00001     Document Type: Review

References (83)

1. Isolation and structure of bryostatin-1
2. Chemistry and clinical biology of the bryostatins
3. Foul medicine
4. Modulation of protein kinase C in antitumor treatment
5. In vivo administration of the anticancer agent bryostatin-1 activates platelets and neutrophils and modulates protein kinase C activity
6. Ubiquitination of protein kinase C-alpha and degradation by the proteasome
7. Biosynthetic products for anticancer drug design and treatment: The bryostatins
8. The catalytic domain of PKC delta confers protection from down-regulation induced by bryostatin-1
9. The bryostatins inhibit growth of B16/F10 melanoma cells in vitro through a protein kinase C-independent mechanism: Dissociation of activities using 26-epi-bryostatin-1
10. Bryostatin-1 induces biphasic activation of protein kinase D in intact cells
11. Role for serine phosphorylation of bcl-2 in an antiapoptotic signaling pathway triggered by IL-3, EPO and bryostatin
12. A functional role for mitochondrial protein kinase C alpha in Bcl2 phosphorylation and suppression of apoptosis
13. Bax:bcl-2 ratio modulation by bryostatin-1 and novel anti-tubulin agents is important for susceptibility to drug-induced apoptosis in the human early pre-B acute lymphoblastic leukemia cell line, Reh
14. Potentiation of 2-chlorodeoxyadenosine activity by bryostatin-1 in the resistant chronic lymphocytic leukemia cell line (WSU-CLL): Association with increased ratios of dCK/5′'NT and Bax/Bcl-2
15. Effect of bryostatin-1 on taxol-induced apoptosis and cytotoxicity in human leukemia cells (U937)
16. Bryostatin-1 downregulates mdr-1 and enhances adriamycin-induced cytotoxicity in human prostate cancer cells
17. Bryostatin-1 down regulates mdr1 and potentiates vincristine cytotoxicity in diffuse large cell lymphoma xenografts
18. Bryostatin-1 affects P-glycoprotein phosphorylation but not function in multidrug resistant human breast cancer cells
19. The antineoplastic agent bryostatin1 induces proinflammatory cytokine production in human monocytes: Synergy with interleukin-2 and modulation of interleukin-2Rgamma chain expression
20. Bryostatins trigger human polymorphonuclear neutrophil and monocyte oxidative metabolism: Association with in vitro antineoplastic activity
21. Varied differentiation responses of human leukemias to bryostatin-1
22. Immunomodulating properties of a novel series of protein kinase C activators. The bryostatins
23. A phase I and immunologic study of bryostatin-1 in patients with solid tumors
24. A phase I trial of bryostatin-1 in patients with advanced malignancy using a 24 hour intravenous infusion
25. Bryostatin-1 activates T-cells that have anti-tumor activity
26. Ex vivo expansion of tumor-draining lymph node cells using compounds which activate intracellular signal transduction. I. Characterization and in vivo anti-tumor activity of glioma-sensitized lymphocytes
27. Adoptive immunotherapy of malignant glioma using tumor-sensitized T-lymphocytes
28. Bryostatin/ionomycin-activated T cells mediate regression of established tumors
29. Adoptive transfer of bryostatin-1 activated T cells provides long term protection from tumor metastases
30. Antineoplastic bryostatins are multipotential stimulators of human hematopoietic progenitor cells
31. The action of bryostatin on normal human hematopoietic progenitors is mediated by accessory cell release of growth factors
32. Modulation of the activity of a human granulocyte-macrophage-colony-stimulating factor/interleukin-3 fusion protein (pIXY 321) by the macrocyclic lactone protein kinase C activator bryostatin 1
33. Bryostatin 1, a unique biologic response modifier: Antileukemic activity in vitro
34. Differentiation and growth modulation of chronic myelogenous leukemia cells by bryostatin
35. Bryostatin 1 induced hairy cell features on chronic lymphocytic leukemia cells in vitro
36. Effect of bryostatin-1 on the in vitro radioprotective capacity of recombinant granulocyte-macrophage colony-stimulating factor (rGM-CSF) toward committed human myeloid progenitor cells (CFU-GM)
37. The macrocyclic lactone protein kinase C activator, bryostatin 1, either alone or in conjunction with recombinant murine granulocyte-macrophage colony-stimulating factor, protects Balb/c and C3H/HeN mice from the lethal in vivo effects of ionizing radiation
38. Radiosensitization of HL-60 human leukemia cells by bryostatin 1 in the absence of increased DNA fragmentation or apoptotic cell death
39. Selective translocation of protein kinase C-delta in PC12 cells during nerve growth factor-induced neuritogenesis
40. A role for zeta protein kinase C in nerve growth factor-induced differentiation of PC12 cells
41. Potentiation of ara-C-induced apoptosis by the protein kinase C activator bryostatin 1 in human leukemia cells (HL60) involves a process dependent upon c-myc
42. Sensitization of human cervical carcinoma cells to cisdiamminedichloroplatinum(II) by bryostatin 1
43. Sequential treatment of human chronic lymphocytic leukemia with bryostatin 1 followed by 2-chlorodeoxyadenosine: Preclinical studies
44. Treatment of a de novo fludarabine-resistant-CLL xenograft model with bryostatin 1 followed by fludarabine
45. Successful treatment of human Waldenstroms macroglobulinemia with combination biological and chemotherapy agents
46. The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model
47. Synergistic interaction of selected marine animal anticancer drugs against human diffuse large cell lymphoma
48. The in vivo effect of bryostatin-1 on paclitaxel-induced tumor growth, mitotic entry and blood flow
49. Preclinical pharmacology of the natural product anticancer agent bryostatin 1, an activator of protein kinase C
50. Comparison of the antitumor activity of bryostatins 1, 5 and 8
51. 3H]bryostatin 1 and analogs to calcium-dependent and calcium-independent protein kinase C isozymes
52. A phase I study of intravenous bryostatin 1 in patients with advanced cancer
53. Phase I study of bryostatin 1: Assessment of Interleukin 6 and tumor necrosis factor induction in vivo
54. Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: In vitro versus in vivo activity
55. Phase I study of bryostatin 1 in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia
56. Compatibility and stability of bryostatin 1 in infusion devices
57. A phase II trial of bryostatin 1 in patients with non-Hodgkins lymphoma
58. A phase I trial of bryostatin-1 in children with refractory solid tumors: A pediatric oncology group study
59. A phase II study of bryostatin 1 in metastatic malignant melanoma
60. Treatment of patients with metastatic melanoma with bryostatin-1 - A phase II study
61. NCIC CTG randomized phase II study of two schedules of bryostatin 1 (NSC339555) in patients with advanced malignant melanoma (IND.104)
62. A phase II trial of bryostatin-1 for patients with metastatic renal cell carcinoma
63. A phase II trial of bryostatin 1 in the treatment of metastatic colorectal cancer
64. Phase II trial of bryostatin 1 in patients with relapsed low-grade non-Hodgkins lymphoma and chronic lymphocytic leukemia
65. A phase II trial of weekly bryostatin-1 in metastatic renal cell carcinoma
66. Phase II studies of bryostatin-1 in patients with advanced sarcoma and advanced head and neck cancer
67. Phase II evaluation of bryostatin-1 in metastatic melanoma
68. Phase II study of bryostatin-1 in patients with relapsed multiple myeloma
69. 31p magnetic resonance spectroscopic study
70. Modulation of bryostatin 1 muscle toxicity by nifedipine: Effects on muscle metabolism and oxygen supply
71. Phase Ib trial of bryostatin 1 in patients with refractory malignancies
72. A sensitive platelet activation-based functional assay for the antileukemic agent bryostatin 1
73. Phase I trial of the PKC activator/downregulator bryostatin 1 (NSC 339555) and high dose ara-C (HiDAC) in patients with refractory acute leukemia
74. Sequential treatment of a resistant chronic lymphocytic leukemia patient with bryostatin-1 followed by 2-chlorodeoxyadenosine: Case report
75. Phase I trial of the PKC activator bryostatin 1 (NSC339555) and F-Ara-Amp (fludarabine) in patients with progressive CLL and refractory indolent non-Hodgkins lymphoma
76. Phase I study of bryostatin-1 (NSC 339555) and cisplatin in advanced malignancies
77. Phase I study of bryostatin-1 and cisplatin (CDDP)
78. Bryostatin 1 and cisplatin: A phase I and pharmacodynamic study
79. A phase I trial of weekly sequential bryostatin-1 and paclitaxel in patients with advanced solid tumors
80. Phase I trial of weekly sequential bryostatin-1, cisplatin and paclitaxel in patients with advanced solid tumors
81. Phase I trial of combination bryostatin 1 and vincristine in B-cell malignancies
82. Adoptive immunotherapy of cancer with pharmacologically activated lymph node lymphocytes: A pilot clinical trial
83. Expansion and tumour specific cytokine secretion of bryostatin-activated T cells from cryopreserved axillary lymph nodes of breast cancer patients